Marinus Pharmaceuticals I... (MRNS)
NASDAQ: MRNS
· Real-Time Price · USD
0.55
0.00 (0.00%)
At close: Feb 10, 2025, 3:59 PM
Marinus Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 8.54M | 8.06M | 7.68M | 7.19M | 7.34M | 6.08M | 10.38M | 7.16M | 2.34M | 1.79M | 14.19M | 1.52M | 10.11M | 1.91M | 1.81M |
Cost of Revenue | 714K | 875K | 887K | 1.01M | 455K | 386K | 206K | 292K | 48K | 21.5M | 1.17M | 18.01M | 1.48M | 18.56M | 18.59M |
Gross Profit | 7.83M | 7.18M | 6.79M | 6.18M | 6.88M | 5.7M | 10.17M | 6.87M | 2.29M | -19.7M | 13.02M | -16.49M | 8.64M | -16.66M | -16.79M |
Operating Income | -21.08M | -32.24M | -35.82M | -35.44M | -31.65M | -31.44M | -32.96M | -29.21M | -30.1M | -36.77M | -17.88M | -27.12M | -19.17M | -23.48M | -27.16M |
Interest Income | 598K | 1.11M | 1.46M | 1.75M | 1.9M | 2.13M | 2.34M | 1.74M | 514K | 84K | 12K | 23K | 17K | 16K | 24K |
Pretax Income | -24.23M | -35.83M | -38.67M | -41.77M | -32.97M | -33.47M | -34.73M | -32.67M | 75.04M | -39.43M | -19.36M | -28.3M | -19.51M | -23.82M | -27.14M |
Net Income | -24.23M | -35.83M | -38.67M | -41.77M | -32.97M | -31.93M | -34.57M | -34.31M | 71.63M | -39.43M | -21.05M | -28.3M | -19.51M | -23.82M | -27.14M |
Selling & General & Admin | 12.57M | 16.71M | 18.63M | 15.36M | 14.87M | 15.72M | 15.2M | 14.66M | 13.39M | 17.06M | 11.74M | 10.62M | 9.45M | 6.83M | 10.38M |
Research & Development | 16.33M | 20.9M | 23.99M | 26.26M | 23.66M | 21.41M | 27.93M | 21.42M | 19M | 21.5M | 17.99M | 18.01M | 18.35M | 18.56M | 18.59M |
Other Expenses | n/a | n/a | 36K | n/a | n/a | 47K | 37K | n/a | n/a | -95K | 1.17M | 341K | n/a | -3K | -4K |
Operating Expenses | 28.91M | 37.61M | 42.61M | 41.62M | 38.53M | 37.13M | 43.14M | 36.08M | 32.39M | 38.56M | 30.9M | 28.64M | 27.8M | 25.39M | 28.97M |
Interest Expense | 3.84M | 4.62M | 4.35M | 4.3M | 4.24M | 4.21M | 4.15M | 3.69M | 2.63M | 2.66M | 1.69M | 1.55M | 678K | 351K | n/a |
Selling & Marketing Expenses | n/a | 3.14M | n/a | -364K | n/a | n/a | n/a | -28.7M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 29.62M | 38.34M | 43.5M | 42.63M | 38.98M | 37.52M | 43.34M | 36.37M | 32.44M | 38.56M | 30.9M | 28.64M | 29.28M | 25.39M | 28.97M |
Income Tax Expense | n/a | n/a | 87.72K | n/a | -142K | -1.54M | -157K | 1.64M | 1.75M | n/a | 1.69M | n/a | n/a | n/a | -24K |
Shares Outstanding (Basic) | 57.23M | 57.06M | 56.85M | 56.69M | 53.92M | 52.55M | 51.77M | 44.97M | 37.2M | 37.16M | 36.89M | 36.73M | 36.74M | 36.65M | 36.6M |
Shares Outstanding (Diluted) | 57.23M | 57.06M | 56.85M | 56.69M | 53.92M | 52.55M | 51.77M | 44.97M | 37.91M | 37.16M | 36.89M | 36.75M | 36.74M | 36.66M | 36.6M |
EPS (Basic) | -0.42 | -0.63 | -0.68 | -0.74 | -0.61 | -0.61 | -0.67 | -0.76 | 1.93 | -1.06 | -0.57 | -0.77 | -0.53 | -0.65 | -0.74 |
EPS (Diluted) | -0.42 | -0.63 | -0.68 | -0.74 | -0.61 | -0.61 | -0.67 | -0.76 | 1.89 | -1.06 | -0.57 | -0.77 | -0.53 | -0.65 | -0.74 |
EBITDA | -21.08M | -31.07M | -34.19M | -37.35M | -28.54M | -29.09M | -30.37M | -28.85M | -29.94M | -36.68M | -17.5M | -26.58M | -18.66M | -23.39M | -27.06M |
EBIT | -20.38M | -31.21M | -34.32M | -37.47M | -28.73M | -29.26M | -30.58M | -28.98M | 77.68M | -36.78M | -17.67M | -26.75M | -18.83M | -23.47M | -27.14M |
Depreciation & Amortization | 134K | 140K | 131K | 125K | 186K | 176K | 210K | 139K | 158K | 178K | 165K | 173K | 171K | 165K | 158K |